Bayer-backed Century buys Empirica to create brain cancer CAR-Ts

Century Therapeutics has bought Empirica to drive development of allogeneic cell therapies against the brain cancer glioblastoma. The induced pluripotent stem cell (IPSC) player, which landed a $215 million investment from Bayer last year, acquired Empirica on the strength of work to create a CAR-T treatment for glioblastoma.